References

1. World Health Organization (WHO). Unsafe Abortion: Global and Regional Estimates of the Incidence of Unsafe Abortion and Associated Mortality in 2008, 6th edn. Geneva: WHO; 2011.

2. World Health Organization (WHO). Safe and Unsafe Induced Abortion: Global and Regional Levels in 2008, and Trends during 1995-2008. Geneva: WHO; 2012.

3. Royal College of Obstetricians and Gynaecologists (RCOG). The Care of Women Requesting Induced Abortion. Evidence-based Clinical Guideline No. 7. London: RCOG; 2011.

4. Whitworth M, Bricker L, Neilson JP, Dowswell T. Ultrasound for fetal assessment in early pregnancy. Cochrane Database Syst Rev 2010;4:CD007058.

5. Bracken H, Clark W, Lichtenberg ES, et al. Alternatives to rou­tine ultrasound for eligibility assessment prior to early ter­mination of pregnancy with mifepristone-misoprostol. BJOG 2011;118:17-23.

6. Kaneshiro B, Edelman A, Sneeringer RK, Ponce de Leon RG. Expanding medical abortion: can medical abortion be effectively provided without the routine use of ultrasound? Contraception 2011;83:194-201.

7. Kulier R, Kapp N. Comprehensive analysis of the use of pre­procedure ultrasound for first- and second-trimester abortion. Contraception 2011;83:30-33.

8. World Health Organization (WHO). Clinical Practice Handbook for Safe Abortion. Geneva: WHO; 2014.

9. Saav I, Kopp Kallner H, Fiala C, Gemzell-Danielsson K. Sublingual versus vaginal misoprostol for cervical dilatation 1 or 3 h prior to surgical abortion: a double-blinded RCT. Hum Reprod 2015;30:1314-22.

10. Li CFI, Wong CYG, Chan CP, Ho PC. A study of co-treat- ment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy. Contraception 2003;67:101-105.

11. Li HWR, Wong CYG, Lo SST, Fan SYS. Effect of local lignocaine gel application for pain relief during suction termination of first- trimester pregnancy: a randomized controlled trial.

12. Kan ASY, Ho PC. Pain control in first-trimester suction evacu­ation. IPPF Med Bull 2006;40:4.

13. Royal College of Pathologists (RCPath). Histopathology of Limited or No Clinical Value: Report of a Working Group, 2nd edn. London: RCPath; 2005.

14. Li HWR, Ng EHY, Ho PC. Clinical applications of misoprostol in gynaecology. J Paed Obstet Gynaecol 2010;36:81-88.

15. el-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or va­ginal misoprostol. N Engl J Med 1995;332:983-87.

16. Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, ran­domized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod 2003;18:2315-18.

17. Schaff EA, Fielding SL, Westhoff C, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA 2000;284:1948-53.

18. von Hertzen H, Piaggio G, Wojdyla D, et al. Two mifepristone doses and two intervals of misoprostol administration for ter­mination of early pregnancy: a randomised factorial controlled equivalence trial. BJOG 2009;116:381-89.

19. Faundes A, Fiala C, Tang OS, Velasco A. Misoprostol for the ter­mination of pregnancy up to 12 completed weeks of pregnancy. Int J Gynaecol Obstet 2007;99 Suppl 2:S172-77.

20. Fiala C, Swahn ML, Stephansson O, Gemzell-Danielsson K. The effect of non-steroidal anti-inflammatory drugs on medical abor­tion with mifepristone and misoprostol at 13-22 weeks gestation. Hum Reprod 2005;20:3072-77.

21. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharma­cokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 2007;99 Suppl 2:S160-67.

22. Lee VCY, Ng EHY, Ho PC. Issues in second trimester induced abortion (medical/surgical methods). Best Pract Res Clin Obstet Gynaecol 2010;24:517-27.

23.

24. Chai J, Tang OS, Hong QQ, Chen QF, Cheng LN, Ng E, Ho PC. A randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester med­ical abortion. Hum Reprod 2009;24:320-24.

25. Royal College of Obstetricians and Gynaecologists. The Use of Anti-D ImmunoglobulinforRhesus D Prophylaxis. London: RCOG; 2011.

26. Stanek AM, Bednarek PH, Nichols MD, Jenson JT, Edelman AB. Barriers associated with the failure to return for intrauterine de­vice insertion following first-t rimester abortion. Contraception 2009;79:216-20.

27. Grimes DA, Lopez LM, Schulz KF, Stanwood NL. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev 2010;6:CD001777.

28. Gaffield ME, Kapp N, Ravi A. Use of combined oral contraceptives post abortion. Contraception 2009;80:355-62.

29. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. Geneva: WHO; 2015.

30. McEwing RL, Anderson NG, Meates JB, Allen RB, Phillipson GT, Wells JE. Sonographic appearances of the endometrium after termination of pregnancy in asymptomatic versus symptomatic women. J Ultrasound Med 2009;28:579-86.

31. Rufener SL, Adusumilli S, Weadock WJ, Caoili E. Sonography of uterine abnormalities in postpartum and postabortion pa­tients: a potential pitfall of interpretation. J Ultrasound Med 2008;27:343-48.

32. Cheung KW, Ngu SF, Cheung VYT. Sonographic characteristics of the uterus in asymptomatic women after second-trimester med­ical termination of pregnancy. J Ultrasound Med 2015;34:611-16.